EYLEAA Injection Approved in Europe for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion TARRYTOWN, N.Y. /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that EYLEAA Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema ... (more)
http://www.biospace.com/news_story.aspx?StoryID=307092&full=1
http://www.biospace.com/news_story.aspx?StoryID=307092&full=1
No comments:
Post a Comment